July 24th 2024
Full efficacy and safety results for the phase 3 PURPOSE 1 trial were announced by Gilead at AIDS 2024.
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Treatment Decision-Making for Complex Patients With HIV: Drug Resistance, Adverse Effects, Comorbidities and P...
1.5 Credits / HIV/AIDS
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
Pharmacist Services to Populations at Risk for HIV: Improving Access and Uptake of Preexposure Prophylaxis
1.0 Credit / HIV/AIDS
View More
Biktarvy Indication Expanded by FDA for Resistant HIV
February 27th 2024The new approval is supported by the phase 3 Study 4030, which evaluated the efficacy, safety, and tolerability profile of Biktarvy in a broad range of people with HIV-1 with or without pre-existing NRTI resistance, including those with the M184V/I resistance.